<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370511</url>
  </required_header>
  <id_info>
    <org_study_id>18-006601</org_study_id>
    <nct_id>NCT02370511</nct_id>
  </id_info>
  <brief_title>Mitral Implantation of TRAnscatheter vaLves</brief_title>
  <acronym>MITRAL</acronym>
  <official_title>The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayra Guerrero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henry Ford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to establish the safety and feasibility of the Edwards SAPIEN&#xD;
      XT™and SAPIEN 3™ device and delivery systems in patients with severe symptomatic calcific&#xD;
      mitral valve disease with severe mitral annular calcification who are not candidates for&#xD;
      standard mitral valve surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      A prospective pilot study enrolling extremely high surgical risk patients with symptomatic&#xD;
      severe calcific mitral valve disease undergoing implantation of an Edwards Sapien XT or&#xD;
      SAPIEN 3 valve in the mitral position.&#xD;
&#xD;
      There are three arms in this study evaluating three separate patient populations described&#xD;
      below:&#xD;
&#xD;
        -  Native Mitral Valve with severe Mitral Annular Calcification (MAC): Patients with&#xD;
           symptomatic severe disease of a native mitral valve due to severe mitral annular&#xD;
           calcification.&#xD;
&#xD;
        -  Valve-in-Ring: Patients with symptomatic failing surgical rings resulting in severe&#xD;
           mitral regurgitation or stenosis.&#xD;
&#xD;
        -  Valve-in-Valve: Patients with failing bioprosthetic surgical valves with severe&#xD;
           regurgitation or stenosis&#xD;
&#xD;
      The delivery approaches include: standard transeptal, modified transeptal approach with a&#xD;
      guidewire externalized through a sheath percutaneously placed in the left ventricle, surgical&#xD;
      trasnapical and surgical transatrial delivery approach with or without surgical resection of&#xD;
      the anterior mitral valve (MV) leaflet (in the native mitral valve arm).&#xD;
&#xD;
      The MITRAL Trial site investigative team (heart team) consists of dedicated representatives&#xD;
      from cardiac surgery, interventional cardiology, echocardiology, neurology, study&#xD;
      coordination and other multi-disciplinary team members consistent with a transcatheter aortic&#xD;
      valve replacement (TAVR) model.&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
      Most endpoints were defined following the Mitral Valve Academic Research Consortium (MVARC)&#xD;
      recommendations with minor modifications.73&#xD;
&#xD;
      The primary safety endpoint is: technical success at exit from the cath lab&#xD;
&#xD;
      • Technical success (at exit from the cath lab) is defined as:&#xD;
&#xD;
        -  Successful vascular and/or TA access, delivery and retrieval of the transcatheter valve&#xD;
           delivery system&#xD;
&#xD;
        -  Deployment of a single valve&#xD;
&#xD;
        -  Correct position of transcatheter valve in the mitral annulus&#xD;
&#xD;
        -  Adequate performance of the prosthetic heart valve (mean mitral valve gradient (MVG) &lt;10&#xD;
           mmHg) without residual mitral regurgitation (MR) grade ≥2 (+)&#xD;
&#xD;
        -  No need for additional surgery or re-intervention (includes drainage of pericardial&#xD;
           effusion)&#xD;
&#xD;
        -  The patient leaves the cath lab alive&#xD;
&#xD;
      The primary performance endpoint is: absence of MR grade 2 (+) or greater or mean MVG ≥10&#xD;
      mmHg at 30 days and 1 year.&#xD;
&#xD;
      Secondary safety endpoints include: Procedural success and all -cause mortality at 30 days&#xD;
      and 1 year.&#xD;
&#xD;
        -  Procedural Success (30 days) in defined as:&#xD;
&#xD;
             -  Device success at 30 days&#xD;
&#xD;
             -  No device/procedure related severe adverse event (SAE's) including: death, stroke,&#xD;
                MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis,&#xD;
                life threatening bleeding, major vascular or access complications (arterial,&#xD;
                venous, or TA - any event requiring additional unplanned surgical or transcatheter&#xD;
                intervention), pericardial effusion or tamponade requiring drainage, severe&#xD;
                hypotension, heart failure or respiratory failure requiring intravenous pressors or&#xD;
                invasive or mechanical treatments such as ultrafiltration or hemodynamic assist&#xD;
                devices including intra-aortic balloon pump or left ventricular assist device, or&#xD;
                prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration,&#xD;
                thrombosis, or other complication requiring surgery or repeat intervention.&#xD;
&#xD;
        -  Device success is defined as:&#xD;
&#xD;
             -  Stroke free survival with original valve in place&#xD;
&#xD;
             -  No need for additional surgery or re-intervention related to the procedure, access&#xD;
                or to the replacement valve&#xD;
&#xD;
             -  Proper placement and intended function of the replacement valve, including&#xD;
&#xD;
             -  No migration, fracture, thrombosis, hemolysis or endocarditis&#xD;
&#xD;
             -  No replacement valve stenosis (MV gradient &lt; 10 mmHg)&#xD;
&#xD;
             -  Replacement valve regurgitation &lt; 2 + (including central and paravalvular leak) and&#xD;
                without associated hemolysis&#xD;
&#xD;
             -  No increase in AI from baseline (more than 1 grade) and LVOT gradient &lt; 20 mmHg&#xD;
                increase from baseline&#xD;
&#xD;
      Additional secondary safety and effectiveness endpoints will be evaluated at two time points:&#xD;
      (1) acute, covering events occurring out to 30 days or hospital discharge, whichever is&#xD;
      longer; and (2) longer-term, covering events from 31 days to 1 year, and include the&#xD;
      following:&#xD;
&#xD;
      Additional Safety Endpoints:&#xD;
&#xD;
      Freedom from&#xD;
&#xD;
        -  all stroke and TIA (MVARC)&#xD;
&#xD;
        -  myocardial infarction&#xD;
&#xD;
        -  major vascular complication (MVARC)&#xD;
&#xD;
        -  life-threatening bleeding (MVARC)&#xD;
&#xD;
        -  mitral valve reoperation or catheter-based intervention for: valve thrombosis, valve&#xD;
           displacement, or other valve placed procedure-related complication&#xD;
&#xD;
        -  hemolysis&#xD;
&#xD;
        -  endocarditis&#xD;
&#xD;
        -  moderate or severe central mitral insufficiency ≥ 2 (+), and/or moderate or severe&#xD;
           perivalvular leak causing ≥ 2 (+) mitral insufficiency&#xD;
&#xD;
        -  significant mitral stenosis (mean MVG &gt;10 mmHg)&#xD;
&#xD;
        -  new permanent pacemaker insertion&#xD;
&#xD;
        -  new aortic valve dysfunction (difference greater than 1(+) severity compared with&#xD;
           baseline)&#xD;
&#xD;
        -  new LVOT gradient ≥ 20 mmHg, or ≥ 20 mmHg increase from baseline LVOT gradient.&#xD;
&#xD;
        -  acute kidney injury (MVARC)&#xD;
&#xD;
        -  new onset atrial fibrillation&#xD;
&#xD;
        -  blood transfusion&#xD;
&#xD;
        -  access site infection&#xD;
&#xD;
        -  need for iatrogenic ASD closure after index procedure&#xD;
&#xD;
      Additional Effectiveness Endpoints:&#xD;
&#xD;
        1. Rehospitalization at 1 year and Total days alive and out of hospital (from date of index&#xD;
           procedure)&#xD;
&#xD;
        2. Clinical improvement per NYHA Class (from baseline) by at least 1 class.&#xD;
&#xD;
        3. Clinical improvement per Quality of Life instruments (&gt;10 points from baseline): (KCCQ&#xD;
           12) (Appendix N)&#xD;
&#xD;
        4. Clinical improvement per 6 Minute Walk Test (&gt; 50 meters from baseline) and 5 meter walk&#xD;
           test. (Appendix H)&#xD;
&#xD;
        5. Mean ICU and total index procedure hospital length of stay&#xD;
&#xD;
      Additional Valve Performance Endpoints:&#xD;
&#xD;
        1. Freedom from major mitral paravalvular leak&#xD;
&#xD;
        2. Improvement in hemodynamic function: mean gradient&#xD;
&#xD;
        3. Freedom from structural valve deterioration&#xD;
&#xD;
        4. Total mitral regurgitation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success at Exit From the Cath Lab.</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subject to achieve technical success (at exit from cath lab) is defined as:&#xD;
Successful vascular delivery and retrieval of transcatheter valve delivery system&#xD;
Deployment of single valve&#xD;
Correct position of transcatheter valve&#xD;
Adequate performance of prosthesis (MVA &gt; 1.5 cm2) without residual MR grade ≥2 (+)&#xD;
No need for additional surgery or re-intervention&#xD;
Patient leaves cath lab alive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of MR Grade 2 (+) or Greater</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitral Valve Gradient (MVG)</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>MVG assessed by echocardiography measured in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Mitral Valve Disease</condition>
  <arm_group>
    <arm_group_label>Native mitral valve with severe MAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valve-in-Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valve-in-Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Mitral Valve Replacement</intervention_name>
    <description>Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
    <arm_group_label>Native mitral valve with severe MAC</arm_group_label>
    <arm_group_label>Valve-in-Ring</arm_group_label>
    <arm_group_label>Valve-in-Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria in Native Mitral Valve arm&#xD;
&#xD;
        All Candidates must meet the following criteria:&#xD;
&#xD;
          1. Patient has severe calcific native mitral valve stenosis with mitral annular&#xD;
             calcification with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2,&#xD;
             or severe mitral regurgitation with severe mitral annular calcification and at least&#xD;
             moderate mitral valve stenosis. Qualifying echo must be within 60 days of the date of&#xD;
             the procedure.&#xD;
&#xD;
          2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA&#xD;
             Functional Class II or greater, or symptoms during stress test.&#xD;
&#xD;
          3. The patient is at least 22 years old.&#xD;
&#xD;
          4. The heart team agrees (and verified in the case review process) that valve&#xD;
             implantation will likely benefit the patient.&#xD;
&#xD;
          5. The heart team agrees that medical factors preclude operation, based on a conclusion&#xD;
             that the probability of death or serious, irreversible morbidity exceeds the&#xD;
             probability of meaningful improvement. Specifically, the STS score is ≥15% or the&#xD;
             probability of death or serious, irreversible morbidity is ≥ 50%. The surgeons'&#xD;
             consult notes shall specify the medical or anatomic factors leading to that conclusion&#xD;
             and include a printout of the calculation of the STS score to additionally identify&#xD;
             the risks in the patient (some medical factors and definitions are provided below). At&#xD;
             least one of the cardiac surgeon assessors must have physically evaluated the patient.&#xD;
             All patients must be approved by the Patient Selection and Procedure Management&#xD;
             Steering Committee (at least 2 member votes, one must be a cardiac surgeon).&#xD;
&#xD;
          6. The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board (IRB) of the respective clinical site.&#xD;
&#xD;
          7. The study patient agrees to comply with all required post-procedure follow-up visits&#xD;
             including annual visits through 5 years and analysis close date visits, which will be&#xD;
             conducted as a phone follow-up.&#xD;
&#xD;
        Inclusion Criteria in Valve-in-Ring arm&#xD;
&#xD;
        All Candidates must meet the following criteria:&#xD;
&#xD;
          1. Patient has a failing surgical ring in the mitral position with severe mitral&#xD;
             regurgitation or stenosis (echocardiographically derived mitral valve area [MVA] of&#xD;
             ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.&#xD;
&#xD;
          2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA&#xD;
             Functional Class II or greater, or symptoms during stress test, or severe hemolytic&#xD;
             anemia requiring blood transfusions and no other cause of hemolytic anemia is found&#xD;
             after extensive work up.&#xD;
&#xD;
        Inclusion Criteria items #3 to 7 will be the same as in Native MV arm described above&#xD;
&#xD;
        Inclusion Criteria in Valve-in-Valve arm&#xD;
&#xD;
        All Candidates must meet the following criteria:&#xD;
&#xD;
          1. Patient has a failing surgical bioprosthesis in the mitral position with severe mitral&#xD;
             regurgitation or stenosis with echocardiographically derived mitral valve area (MVA)&#xD;
             of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.&#xD;
&#xD;
          2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA&#xD;
             Functional Class II or greater, or symptoms during stress test.&#xD;
&#xD;
        Inclusion Criteria items #3 to 7 will be the same as in Native MV arm described above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Candidates will be excluded from the study if any of the following conditions are present:&#xD;
&#xD;
          1. Heart Team assessment of operability (the heart team considers the patient is a&#xD;
             surgical candidate).&#xD;
&#xD;
          2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended&#xD;
             treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥&#xD;
             twice normal in the presence of MB elevation and/or troponin level elevation (WHO&#xD;
             definition)].&#xD;
&#xD;
          3. Mitral annulus is not calcified (only applies to patients included in Native MV arm).&#xD;
&#xD;
          4. Complex untreated coronary artery disease:&#xD;
&#xD;
               1. Unprotected left main coronary artery&#xD;
&#xD;
               2. Syntax score &gt; 32 (in the absence of prior revascularization)&#xD;
&#xD;
          5. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is&#xD;
             performed within 30 days of the index procedure (unless part of planned strategy for&#xD;
             treatment of concomitant coronary artery disease). Implantation of a permanent&#xD;
             pacemaker is not excluded.&#xD;
&#xD;
          6. Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless&#xD;
             BMV is a bridge to procedure after a qualifying ECHO).&#xD;
&#xD;
          7. Patients with planned concomitant surgical or transcatheter ablation for Atrial&#xD;
             Fibrillation.&#xD;
&#xD;
          8. Leukopenia (WBC &lt; 3000 cell/mL), acute anemia (Hgb &lt; 9 g/dL), Thrombocytopenia (Plt &lt;&#xD;
             50,000 cell/mL).&#xD;
&#xD;
          9. Hypertrophic obstructive cardiomyopathy (HOCM).&#xD;
&#xD;
         10. Hemodynamic or respiratory instability requiring inotropic support, mechanical&#xD;
             ventilation or mechanical heart assistance within 30 days of screening evaluation.&#xD;
&#xD;
         11. Need for emergency surgery for any reason.&#xD;
&#xD;
         12. Severe ventricular dysfunction with LVEF &lt; 20%.&#xD;
&#xD;
         13. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.&#xD;
&#xD;
         14. Active upper GI bleeding within 3 months (90 days) prior to procedure.&#xD;
&#xD;
         15. A known contraindication or hypersensitivity to all anticoagulation regimens, or&#xD;
             inability to be anticoagulated for the study procedure.&#xD;
&#xD;
         16. For patients enrolled in the Native MV arm: Native mitral annulus size &lt; 275 mm2 or &gt;&#xD;
             740 mm2 as measured by CT scan.&#xD;
&#xD;
             For patients in Valve-in-Ring arm: surgical ring with a true mean internal diameter&#xD;
             ≤18 mm or ≥ 29 mm or an area &lt; 275 mm2 or &gt; 740 mm2 as measured by CT scan. Caution&#xD;
             recommended in:&#xD;
&#xD;
               -  Incomplete bands due to risk of paravalvular leak and risk of LVOT obstruction.&#xD;
                  Careful measurements by CT and CT-guided procedural planning is recommended.&#xD;
&#xD;
               -  Non-circular rigid or semi-flexible rings (e.g., D-shaped, saddle shaped, etc)&#xD;
                  due to risk of para-valvular leak and/or out of round or incomplete valve&#xD;
                  expansion.&#xD;
&#xD;
             For patients in Valve-in-Valve arm: surgical bioprosthesis with a true internal&#xD;
             diameter ≤18 mm or ≥ 29 mm&#xD;
&#xD;
         17. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic&#xD;
             attack (TIA) within 6 months (180 days) of the procedure.&#xD;
&#xD;
         18. Estimated life expectancy &lt; 24 months (730 days) due to carcinomas, chronic liver&#xD;
             disease, chronic renal disease or chronic end stage pulmonary disease.&#xD;
&#xD;
         19. Expectation that patient will not improve despite treatment of mitral stenosis&#xD;
&#xD;
         20. Active bacterial endocarditis within 6 months (180 days) of procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayra E. Guerrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont HealtCare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital / North Shore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>48107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Guerrero M, Greenbaum A, O'Neill W. First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):E287-91. doi: 10.1002/ccd.25441. Epub 2014 Mar 14.</citation>
    <PMID>24532349</PMID>
  </reference>
  <reference>
    <citation>Sinning JM, Mellert F, Schiller W, Welz A, Nickenig G, Hammerstingl C. Transcatheter mitral valve replacement using a balloon-expandable prosthesis in a patient with calcified native mitral valve stenosis. Eur Heart J. 2013 Sep;34(33):2609. doi: 10.1093/eurheartj/eht254. Epub 2013 Jul 4.</citation>
    <PMID>23828829</PMID>
  </reference>
  <reference>
    <citation>Hasan R, Mahadevan VS, Schneider H, Clarke B. First in human transapical implantation of an inverted transcatheter aortic valve prosthesis to treat native mitral valve stenosis. Circulation. 2013 Aug 6;128(6):e74-6. doi: 10.1161/CIRCULATIONAHA.113.001466.</citation>
    <PMID>23918190</PMID>
  </reference>
  <reference>
    <citation>Fassa AA, Himbert D, Brochet E, Depoix JP, Cheong AP, Alkhoder S, Nataf P, Vahanian A. Transseptal transcatheter mitral valve implantation for severely calcified mitral stenosis. JACC Cardiovasc Interv. 2014 Jun;7(6):696-7. doi: 10.1016/j.jcin.2013.12.204. Epub 2014 May 14.</citation>
    <PMID>24835326</PMID>
  </reference>
  <reference>
    <citation>Ribeiro HB, Doyle D, Urena M, Allende R, Amat-Santos I, Pasian S, Bilodeau S, Mohammadi S, Paradis JM, DeLarochellière R, Rodés-Cabau J, Dumont E. Transapical mitral implantation of a balloon-expandable valve in native mitral valve stenosis in a patient with previous transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014 Oct;7(10):e137-9. doi: 10.1016/j.jcin.2014.02.024. Epub 2014 Sep 17.</citation>
    <PMID>25240553</PMID>
  </reference>
  <reference>
    <citation>Ferrari E, Niclauss L, Locca D, Marcucci C. On-pump fibrillating heart mitral valve replacement with the SAPIEN™ XT transcatheter heart valve. Eur J Cardiothorac Surg. 2014 Apr;45(4):749-51. doi: 10.1093/ejcts/ezt364. Epub 2013 Jul 11.</citation>
    <PMID>23847181</PMID>
  </reference>
  <reference>
    <citation>Himbert D, Bouleti C, Iung B, Nejjari M, Brochet E, Depoix JP, Ghodbane W, Fassa AA, Nataf P, Vahanian A. Transcatheter valve replacement in patients with severe mitral valve disease and annular calcification. J Am Coll Cardiol. 2014 Dec 16;64(23):2557-8. doi: 10.1016/j.jacc.2014.09.047.</citation>
    <PMID>25500243</PMID>
  </reference>
  <results_reference>
    <citation>Guerrero M, Wang DD, Eleid MF, Pursnani A, Salinger M, Russell HM, Kodali SK, George I, Bapat VN, Dangas GD, Tang GHL, Inglesis I, Meduri CU, Palacios I, Reisman M, Whisenant BK, Jermihov A, Kaptzan T, Lewis BR, Tommaso C, Krause P, Thaden J, Oh JK, Douglas PS, Hahn RT, Leon MB, Rihal CS, Feldman T, O'Neill WW. Prospective Study of TMVR Using Balloon-Expandable Aortic Transcatheter Valves in MAC: MITRAL Trial 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):830-845. doi: 10.1016/j.jcin.2021.01.052.</citation>
    <PMID>33888229</PMID>
  </results_reference>
  <results_reference>
    <citation>Guerrero M, Wang DD, Pursnani A, Salinger M, Russell HM, Eleid M, Chakravarty T, Ng MH, Kodali SK, Meduri CU, Pershad A, Satler L, Waksman R, Palacios I, Smalling R, Reisman M, Gegenhuber M, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Douglas PS, Hahn RT, Kar S, Makkar R, Leon MB, Feldman T, Rihal C, O'Neill WW. Prospective Evaluation of TMVR for Failed Surgical Annuloplasty Rings: MITRAL Trial Valve-in-Ring Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):846-858. doi: 10.1016/j.jcin.2021.01.051.</citation>
    <PMID>33888230</PMID>
  </results_reference>
  <results_reference>
    <citation>Guerrero M, Pursnani A, Narang A, Salinger M, Wang DD, Eleid M, Kodali SK, George I, Satler L, Waksman R, Meduri CU, Rajagopal V, Inglessis I, Palacios I, Reisman M, Eng MH, Russell HM, Pershad A, Fang K, Kar S, Makkar R, Saucedo J, Pearson P, Bokhary U, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Lang RM, Hahn RT, Leon MB, O'Neill WW, Feldman T, Rihal C. Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):859-872. doi: 10.1016/j.jcin.2021.02.027.</citation>
    <PMID>33888231</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <results_first_submitted>June 24, 2021</results_first_submitted>
  <results_first_submitted_qc>July 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2021</results_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mayra Guerrero</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02370511/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Native Mitral Valve With Severe MAC</title>
          <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="P2">
          <title>Valve-in-Ring</title>
          <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="P3">
          <title>Valve-in-Valve</title>
          <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Native Mitral Valve With Severe MAC</title>
          <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="B2">
          <title>Valve-in-Ring</title>
          <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="B3">
          <title>Valve-in-Valve</title>
          <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" lower_limit="71.3" upper_limit="81.0"/>
                    <measurement group_id="B2" value="71.5" lower_limit="67.0" upper_limit="76.8"/>
                    <measurement group_id="B3" value="77.5" lower_limit="70.3" upper_limit="82.8"/>
                    <measurement group_id="B4" value="75.5" lower_limit="67.75" upper_limit="82.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Technical Success at Exit From the Cath Lab.</title>
        <description>Number of subject to achieve technical success (at exit from cath lab) is defined as:&#xD;
Successful vascular delivery and retrieval of transcatheter valve delivery system&#xD;
Deployment of single valve&#xD;
Correct position of transcatheter valve&#xD;
Adequate performance of prosthesis (MVA &gt; 1.5 cm2) without residual MR grade ≥2 (+)&#xD;
No need for additional surgery or re-intervention&#xD;
Patient leaves cath lab alive</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Native Mitral Valve With Severe MAC</title>
            <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O2">
            <title>Valve-in-Ring</title>
            <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O3">
            <title>Valve-in-Valve</title>
            <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success at Exit From the Cath Lab.</title>
          <description>Number of subject to achieve technical success (at exit from cath lab) is defined as:&#xD;
Successful vascular delivery and retrieval of transcatheter valve delivery system&#xD;
Deployment of single valve&#xD;
Correct position of transcatheter valve&#xD;
Adequate performance of prosthesis (MVA &gt; 1.5 cm2) without residual MR grade ≥2 (+)&#xD;
No need for additional surgery or re-intervention&#xD;
Patient leaves cath lab alive</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absence of MR Grade 2 (+) or Greater</title>
        <description>Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.</description>
        <time_frame>30 days and 1 year</time_frame>
        <population>For MAC arm at 30 days 5 patients died and one withdrew consent and at 1 yr 5 additional patients died, 1 additional withdrew consent and 1 additional did not complete 1 yr follow up. For Valve-in-Ring arm at 30 days 2 patients died and at 1 yr 5 additional patients died, 1 patient lost to follow up and 3 did not complete 1 yr follow up. For Valve-in-Valve arm 1 patient died. Data was not collected or analyzed for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Native Mitral Valve With Severe MAC</title>
            <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O2">
            <title>Valve-in-Ring</title>
            <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O3">
            <title>Valve-in-Valve</title>
            <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of MR Grade 2 (+) or Greater</title>
          <description>Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.</description>
          <population>For MAC arm at 30 days 5 patients died and one withdrew consent and at 1 yr 5 additional patients died, 1 additional withdrew consent and 1 additional did not complete 1 yr follow up. For Valve-in-Ring arm at 30 days 2 patients died and at 1 yr 5 additional patients died, 1 patient lost to follow up and 3 did not complete 1 yr follow up. For Valve-in-Valve arm 1 patient died. Data was not collected or analyzed for these patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mitral Valve Gradient (MVG)</title>
        <description>MVG assessed by echocardiography measured in mmHg</description>
        <time_frame>30 days and 1 year</time_frame>
        <population>For MAC arm at 30 days 5 patients died and one withdrew consent and at 1 yr 5 additional patients died, 1 additional withdrew consent and 1 additional did not complete 1 yr follow up. For Valve-in-Ring arm at 30 days 2 patients died and at 1 yr 5 additional patients died, 1 patient lost to follow up and 3 did not complete 1 yr follow up. For Valve-in-Valve arm 1 patient died. Data was not collected or analyzed for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Native Mitral Valve With Severe MAC</title>
            <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O2">
            <title>Valve-in-Ring</title>
            <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O3">
            <title>Valve-in-Valve</title>
            <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Gradient (MVG)</title>
          <description>MVG assessed by echocardiography measured in mmHg</description>
          <population>For MAC arm at 30 days 5 patients died and one withdrew consent and at 1 yr 5 additional patients died, 1 additional withdrew consent and 1 additional did not complete 1 yr follow up. For Valve-in-Ring arm at 30 days 2 patients died and at 1 yr 5 additional patients died, 1 patient lost to follow up and 3 did not complete 1 yr follow up. For Valve-in-Valve arm 1 patient died. Data was not collected or analyzed for these patients.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.2" upper_limit="7.8"/>
                    <measurement group_id="O2" value="7.6" lower_limit="5.9" upper_limit="9.1"/>
                    <measurement group_id="O3" value="6.0" lower_limit="4.7" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.6" upper_limit="7.1"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4.7" upper_limit="7.3"/>
                    <measurement group_id="O3" value="6.6" lower_limit="5.5" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.</description>
        <time_frame>30 days</time_frame>
        <population>For MAC arm 1 withdrew consent data was not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Native Mitral Valve With Severe MAC</title>
            <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O2">
            <title>Valve-in-Ring</title>
            <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
          <group group_id="O3">
            <title>Valve-in-Valve</title>
            <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.</description>
          <population>For MAC arm 1 withdrew consent data was not collected or analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected all subjects from baseline to end of study, approximately one year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Native Mitral Valve With Severe MAC</title>
          <description>Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="E2">
          <title>Valve-in-Ring</title>
          <description>Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
        <group group_id="E3">
          <title>Valve-in-Valve</title>
          <description>Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).&#xD;
Transcatheter Mitral Valve Replacement: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mitral valve reintervention after index procedure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>New permanent pacemaker requirement</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>New rehospitalization for heart failure</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Valve thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood transfusion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mayra Guerrero</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-1267</phone>
      <email>Guerrero.Mayra@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

